Form 4: Aurinia Director Boosts Stake with $14.5M Share Purchase

Aurinia Pharmaceuticals Inc. Director Kevin Tang significantly increased his indirect beneficial ownership through multiple common share purchases totaling 1.3 million shares.

Summary

• Director Kevin Tang acquired a total of 1,300,000 common shares of Aurinia Pharmaceuticals Inc. (AUPH) through three separate transactions.
• On August 1, 2025, 1,000,000 common shares were purchased at a weighted-average price of $10.12 per share, with prices ranging from $9.23 to $10.50.
• On August 4, 2025, an additional 100,000 common shares were acquired at a weighted-average price of $11.34 per share, with prices ranging from $11.11 to $11.48.
• On August 5, 2025, 200,000 common shares were purchased at a weighted-average price of $11.68 per share, with prices ranging from $11.49 to $11.80.
• Following these transactions, Kevin Tang's indirect beneficial ownership stands at 11,329,500 common shares.
• The shares are beneficially owned by Tang Capital Partners, LP (6,371,711 shares) and Tang Capital Partners International, LP (4,957,789 shares), with Kevin Tang being the sole manager of the general partner for both LPs and having a pecuniary interest in the shares.

Sentiment

Score: 8

Explanation: The significant insider buying by a director is a strong positive signal, indicating high confidence in the company's future performance and valuation.

Positives

• Significant insider buying by a director indicates strong confidence in the company's future prospects and valuation.
• The substantial increase in beneficial ownership aligns the director's interests more closely with those of other shareholders.
• Purchases occurred at varying price points, suggesting a sustained belief in the company's value proposition.

Future Outlook

NA

Industry Context

This insider buying activity within the biotechnology and pharmaceutical sector can be interpreted as a positive signal, suggesting that a key insider believes the company's current valuation does not fully reflect its potential, especially given the inherent risks and long development cycles in the industry.

Related Party Transactions

• The shares were purchased by Tang Capital Partners, LP and Tang Capital Partners International, LP, which are investment vehicles where Kevin Tang serves as the sole manager of the general partner and has a pecuniary interest, classifying these as indirect beneficial ownership transactions related to the director.

Stakeholder Impact

• Shareholders may view this as a positive sign, as increased insider ownership often aligns management's interests with shareholder value creation.
• The market may react positively to the news, potentially leading to increased investor confidence and share price appreciation.

Key Dates

Recommendation

The substantial share purchases by Director Kevin Tang, totaling 1.3 million shares across three transactions, signal strong insider confidence in Aurinia Pharmaceuticals Inc.'s valuation and future performance. This significant increase in beneficial ownership, particularly at varying price points, suggests a belief that the stock is undervalued or poised for growth, making it a compelling 'buy' signal for investors.

Keywords

Aurinia Pharmaceuticals, AUPH, Insider Buying, Kevin Tang, SEC Form 4, Share Purchase, Director Stake, Biotechnology, Pharmaceuticals, Investment